Payment overview · 2025
General Payments
$745.06
40 reported records · 9 companies
Healthcare provider profile · identity verified
Wallace B Purdy, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1528166832
Verified facts
What the public records show
CMS Open Payments records show Wallace B Purdy, M.D. received $745.06 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $228.62 | 30.7% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.15 | 14.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $98.39 | 13.2% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $94.23 | 12.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.95 | 9.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.35 | 6.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.04 | 6.8% | 2 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $28.04 | 3.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.29 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $745.06 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $129.82 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $98.39 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $94.23 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.33 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $81.03 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.95 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.35 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.35 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.04 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.04 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.31 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 212 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 160 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 319 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 257 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
160 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
319 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
257 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 958 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 955 | 250 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 880 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 772 | 202 |
| Potassium Chloride | Potassium Chloride | 635 | 168 |
| Losartan Potassium | Losartan Potassium | 569 | 140 |
| Gabapentin | Gabapentin | 541 | 123 |
| Trazodone Hcl | Trazodone Hcl | 523 | 108 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 520 | 115 |
| Omeprazole | Omeprazole | 488 | 118 |
| Zolpidem Tartrate | Zolpidem Tartrate | 431 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 429 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 419 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 384 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 370 | 92 |
| Furosemide | Furosemide | 335 | 87 |
| Mounjaro | Tirzepatide | 319 | 47 |
| Tramadol Hcl | Tramadol Hcl | 305 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 302 | 41 |
| Clonazepam | Clonazepam | 297 | 37 |
| Atenolol | Atenolol | 296 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 65 |
| Ezetimibe | Ezetimibe | 288 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 284 | 73 |
| Metformin Hcl | Metformin Hcl | 276 | 74 |
| Ozempic | Semaglutide | 257 | 41 |
| Lisinopril | Lisinopril | 252 | 64 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 237 | 69 |
| Glimepiride | Glimepiride | 233 | 58 |
| Eliquis | Apixaban | 212 | 42 |
| Lorazepam | Lorazepam | 200 | 26 |
| Metformin Hcl Er | Metformin Hcl | 196 | 54 |
| Simvastatin | Simvastatin | 194 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 50 |
| Famotidine | Famotidine | 187 | 47 |
| Carvedilol | Carvedilol | 183 | 39 |
| Montelukast Sodium | Montelukast Sodium | 183 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 172 | 55 |
| Labetalol Hcl | Labetalol Hcl | 171 | 35 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 170 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 39 |
| Farxiga | Dapagliflozin Propanediol | 160 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 158 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 157 | 35 |
| Sertraline Hcl | Sertraline Hcl | 155 | 37 |
| Allopurinol | Allopurinol | 152 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 145 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 142 | 30 |
| Clonidine Hcl | Clonidine Hcl | 139 | 32 |
| Methocarbamol | Methocarbamol | 134 | 31 |
| Finasteride | Finasteride | 133 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 26 |
| Meloxicam | Meloxicam | 130 | 36 |
| Azithromycin | Azithromycin | 126 | 99 |
| Pregabalin | Pregabalin | 126 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 29 |
| Lovastatin | Lovastatin | 116 | 29 |
| Celecoxib | Celecoxib | 114 | 27 |
| Buspirone Hcl | Buspirone Hcl | 110 | 24 |
| Spironolactone | Spironolactone | 106 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 28 |
| Amoxicillin | Amoxicillin | 101 | 81 |
| Aripiprazole | Aripiprazole | 101 | 23 |
| Alendronate Sodium | Alendronate Sodium | 89 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 29 |
| Topiramate | Topiramate | 82 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 20 |
| Warfarin Sodium | Warfarin Sodium | 78 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 55 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 13 |
| Promethazine Hcl | Promethazine Hcl | 72 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 71 | 23 |
| Diazepam | Diazepam | 70 | suppressed |
| Methylprednisolone | Methylprednisolone | 70 | 47 |
| Prednisone | Prednisone | 70 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 14 |
| Nifedipine Er | Nifedipine | 66 | 15 |
| Jardiance | Empagliflozin | 63 | 14 |
| Mirtazapine | Mirtazapine | 63 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 54 |
| Levetiracetam | Levetiracetam | 62 | 11 |
| Indapamide | Indapamide | 61 | 22 |
| Colchicine | Colchicine | 57 | 18 |
| Ibuprofen | Ibuprofen | 57 | 16 |
| Cilostazol | Cilostazol | 55 | 15 |
| Donepezil Hcl | Donepezil Hcl | 55 | 16 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 40 |
| Xarelto | Rivaroxaban | 53 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 52 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 13 |
| Valacyclovir | Valacyclovir Hcl | 48 | suppressed |
| Chlorthalidone | Chlorthalidone | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Trulicity | Dulaglutide | 43 | 11 |
| Fluconazole | Fluconazole | 42 | 21 |
| Glipizide | Glipizide | 41 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 17 |
| Clotrimazole | Clotrimazole | 38 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 17 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 11 |
| Linzess | Linaclotide | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Belsomra | Suvorexant | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 25 |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 14 |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Mitigare | Colchicine | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Klor-Con 8 | Potassium Chloride | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.06 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error